Semintra

RSS

telmisartan

Authorised
This medicine is authorised for use in the European Union.

Overview

An overview of Semintra and why it is authorised in the EU

Semintra is a veterinary medicine used in cats to reduce proteinuria (protein in the urine) and to treat high blood pressure. Proteinuria can occur with chronic (long-term) kidney disease in cats, a common disease in elderly cats characterised by a progressive deterioration of kidney function over time. High blood pressure is also a long term problem of ageing cats which can occur with chronic kidney disease, hyperthyroidism (overactive thyroid gland) and other conditions.

This EPAR was last updated on 14/01/2019

Authorisation details

Product details
Name
Semintra
Agency product number
EMEA/V/C/002436
Active substance
telmisartan
International non-proprietary name (INN) or common name
telmisartan
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QC09CA07
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
13/02/2013
Contact address

55216 Ingelheim am Rhein
Germany

Product information

07/12/2018 Semintra - EMEA/V/C/002436 - IB/0011

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Agents acting on the renin-angiotensin system

  • Angiotensin II antagonists, plain

Therapeutic indication

Reduction of proteinuria associated with chronic kidney disease (CKD).

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating